Some examples showcasing the various formats of Biointron's previous multispecific
antibody productions.
Bispecific Antibody Production for Research Success with Biointron
The ever-increasing research and clinical demands call for advanced therapeutic antibody drugs, and bispecific antibodies are among the most promising. lmmunoglobulin G (lgG), the most common antibody type in blood circulation, is typically monospecific and recognizes only a single antigen, with the exception of lgG4. In contrast, bispecific antibodies are designed to recognize and bind to two different targets simultaneously, providing enhanced or unique effects through distinct mechanisms.
Certified to ISO 9001:2015 and supported by a global team of 600+ professionals, Biointron offers a fully integrated, high-throughput solution - from gene sequence to purified antibody - in just 2 weeks.
Bispecific antibodies have demonstrated their therapeutic value in clinical settings, as they can be designed to redirect immune cells (such as T cells) toward diseased cells for targeted elimination. Additionally, bispecific antibodies can facilitate the delivery of therapeutic payloads, such as toxins or drugs, to in vivo targets.
Custom Bispecific Antibodies Produced by Biointron
With over 12 years of experience in antibody discovery, expression, and optimization, Biointron has become a trusted partner to more than 3,000 biotech and pharmaceutical companies worldwide. Since 2012, we’ve delivered over 100,000 recombinant antibodies annually.
Choosing the optimal bispecific antibody format and structure is a critical decision influenced by application, manufacturing considerations, and commercial goals. Our expert team is here to guide you through the selection process and support your project every step of the way.
